Oblimersen for the treatment of patients with chronic lymphocytic leukemia

por Cheson, Bruce D
Publicado 2007

Role of bendamustine in the treatment of chronic lymphocytic leukemia

por Jamshed, Saad, Cheson, Bruce D
Publicado 2009

State-of-the-Art Research on “Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response”

por Kostakoglu, Lale, Cheson, Bruce D.
Publicado 2013

Impact of obinutuzumab alone and in combination for follicular lymphoma

por Sarraf Yazdy, Maryam, Cheson, Bruce D
Publicado 2017

Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic

por Chauhan, Ayushi F, Cheson, Bruce D
Publicado 2021

Diffuse large B-cell lymphoma: new targets and novel therapies

por Cheson, Bruce D., Nowakowski, Grzegorz, Salles, Gilles
Publicado 2021

Successful Treatment of Ocular Chronic Lymphocytic Leukemia with Ibrutinib: Case Report and Review of the Literature

por Chauhan, Ayushi F, Viruni, Narine, Alvin Liu, T.Y., Arevalo, J Fernando, Cheson, Bruce D
Publicado 2020

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents

por Cheson, Bruce D., Heitner Enschede, Sari, Cerri, Elisa, Desai, Monali, Potluri, Jalaja, Lamanna, Nicole, Tam, Constantine
Publicado 2017

Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score–matched analysis of E7438-G000-101 trial outcomes

por Proudman, David G., Gupta, Deepshekhar, Nellesen, Dave, Yang, Jay, Kamp, Beth A., Mamlouk, Khalid, Cheson, Bruce D.
Publicado 2022

Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update

por Cheson, Bruce D., Brugger, Wolfram, Damaj, Gandhi, Dreyling, Martin, Kahl, Brad, Kimby, Eva, Ogura, Michinori, Weidmann, Eckhart, Wendtner, Clemens-Martin, Zinzani, Pier Luigi
Publicado 2016

Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas

por Cheson, Bruce D., O’Brien, Susan, Ewer, Michael S., Goncalves, Marcus D., Farooki, Azeez, Lenz, Georg, Yu, Anthony, Fisher, Richard I., Zinzani, Pierre L., Dreyling, Martin
Publicado 2018

Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendam...

por Cheson, Bruce D., Trask, Peter C., Gribben, John G., Dimier, Natalie, Kimby, Eva, Lugtenburg, Pieternella J., Thieblemont, Catherine, Wassner-Fritsch, Elisabeth, Launonen, Aino, Sehn, Laurie H.
Publicado 2016

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial

por Ghia, Paolo, Coutre, Steven E., Cheson, Bruce D., Barrientos, Jacqueline C., Hillmen, Peter, Pettitt, Andrew R., Zelenetz, Andrew D., Shreay, Sanatan, Hallek, Michael, Furman, Richard R.
Publicado 2020

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor

por Wierda, William G., Byrd, John C., Davids, Matthew S., Furman, Richard R., Cheson, Bruce D., Barr, Paul M., Eradat, Herbert, Heffner, Leonard, Zhou, Lang, Verdugo, Maria, Potluri, Jalaja, Choi, Michael
Publicado 2018

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial

por Balasubramanian, Sriram, Hodkinson, Brendan, Schuster, Stephen J., Fowler, Nathan H., Trotman, Judith, Hess, Georg, Cheson, Bruce D., Schaffer, Michael, Sun, Steven, Deshpande, Sanjay, Vermeulen, Jessica, Salles, Gilles, Gopal, Ajay K.
Publicado 2021

The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials

por Lansigan, Frederick, Barak, Ian, Pitcher, Brandelyn, Jung, Sin‐Ho, Cheson, Bruce D., Czuczman, Myron, Martin, Peter, Hsi, Eric, Schöder, Heiko, Smith, Scott, Bartlett, Nancy L., Leonard, John P., Blum, Kristie A.
Publicado 2018

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial

por Pott, Christiane, Sehn, Laurie H., Belada, David, Gribben, John, Hoster, Eva, Kahl, Brad, Kehden, Britta, Nicolas-Virelizier, Emmanuelle, Spielewoy, Nathalie, Fingerle-Rowson, Guenter, Harbron, Chris, Mundt, Kirsten, Wassner-Fritsch, Elisabeth, Cheson, Bruce D.
Publicado 2019

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

por de Vos, Sven, Forero-Torres, Andres, Ansell, Stephen M, Kahl, Brad, Cheson, Bruce D, Bartlett, Nancy L, Furman, Richard R, Winter, Jane N, Kaplan, Henry, Timmerman, John, Whiting, Nancy C, Drachman, Jonathan G, Advani, Ranjana
Publicado 2014

Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab

por Forero, Andres, Hamadani, Mehdi, Kipps, Thomas, Fanale, Michelle, Cuneo, Antonio, Perez de Oteyza, Jaime, Gladstone, Douglas, Andre, Marc, Bellam, Naresh, Goswami, Trishna, Ibrahim, Ramy, Schneider, Amy, Liang, Meina, Eck, Steven, Elgeioushi, Nairouz, Herbst, Ronald, Cheson, Bruce D
Publicado 2013

Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed/refractory chronic lymphocytic leukemia

por Rogers, Kerry A., Thompson, Philip A., Allan, John N., Coleman, Morton, Sharman, Jeff P., Cheson, Bruce D., Jones, Daniel, Izumi, Raquel, Frigault, Melanie M., Quah, Cheng, Raman, Rakesh K., Patel, Priti, Wang, Min Hui, Kipps, Thomas J.
Publicado 2021